Increase in VA Legionnaires' Disease Rates From 2014 to 2016

Share this content:
Increase in VA Legionnaires' Disease Rates From 2014 to 2016
Increase in VA Legionnaires' Disease Rates From 2014 to 2016

MONDAY, June 18, 2018 (HealthDay News) -- There was an increase in Legionnaires' Disease (LD) from 2014 to 2016, according to a study published online June 15 in JAMA Network Open.

Shantini D. Gamage, Ph.D., M.P.H., from the Department of Veterans Affairs (VA) in Washington, D.C., and colleagues conducted a retrospective cohort study of reported LD data in VA medical facilities in a national VA LD surveillance system. A total of 491 LD cases were identified in the surveillance system from Jan. 1, 2014, to Dec. 31, 2016.

The researchers found that 91 percent of cases had no VA exposure or only outpatient VA exposure. The remaining cases had VA exposure from overnight stays. For all VA enrollees and for users of VA health care there were increases in total LD rates from Jan. 1, 2014, to Dec. 31, 2016 (from 1.5 to 2.0 per 100,000 enrollees and from 2.3 to 3.0 per 100,000 enrollees, respectively; both P = 0.04). For the subset who had no VA exposure there was also an increase in LD rate (0.90 to 1.47 per 100,000 enrollees; P < 0.001). There was a decrease in the LD rate for patients with VA overnight stay on a population level (5.0 to 2.3 per 100,000 enrollees) and an exposure level (0.31 to 0.15 per 100,000 enrollees) (both P < 0.001).

"Data in the VA LD databases showed an increase in overall LD rates over the three years, driven by increases in rates of non-VA LD," the authors write. "Inpatient VA-associated LD rates decreased, suggesting that the VA's LD prevention efforts have contributed to improved patient safety."

Abstract/Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Moves to Restrict Flavored E-Cig Sales, Ban Menthol Cigarettes

FDA Moves to Restrict Flavored E-Cig Sales, Ban ...

The move stops short of the full ban on e-cigarettes that had been expected

Name-Brand Medications Driving Spike in U.S. Drug Spending

Name-Brand Medications Driving Spike in U.S. Drug Spending

Greatest costs for Humira, Remicade, Enbrel, Novolog, and Neulasta

is free, fast, and customized just for you!




Already a member?

Sign In Now »